Skip to main content

Aldevron Expands Commercial Leadership Team With Addition of Two Industry Veterans

Aldevron, the world’s leading biomanufacturer of plasmid DNA, mRNA and proteins, is expanding its commercial leadership with the addition of Beth Thompson-Webb as Chief Commercial Officer and Todd Howren as Vice President of Sales.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005080/en/

Beth Thompson-Webb, CCO (Photo: Business Wire)

Beth Thompson-Webb, CCO (Photo: Business Wire)

Thompson-Webb will be responsible for leading Aldevron’s worldwide sales and marketing strategy where she will utilize her 30 years of industry experience to drive strategic growth and service initiatives. Thompson-Webb will report to Kevin Ballinger, CEO, and serve as a member of Aldevron’s senior executive team.

Howren will lead and expand Aldevron’s field sales team efforts in order to better service and address our growing client base. He brings more than 25 years of sales experience in the biotechnology field and will report directly to Thompson-Webb.

“Having Beth as Chief Commercial Officer and Todd as Vice President of Sales accelerates Aldevron’s ability to implement our strategic vision for the next phase of growth,” said Ballinger. “Both Beth and Todd’s proven track record of delivering results solidifies our path of continued growth, while providing a critical level of commercial leadership experience to support our clients and the patients they serve.”

Prior to joining Aldevron, Thompson-Webb was General Manager, Global Commercial for Cell and Gene Therapy at Cytiva (formally GE Healthcare Life Sciences). Under her leadership, the business experienced exceptional year over year growth and was recognized as the fastest growing and highest profile business within GE Healthcare Life Sciences. Since joining Cytiva in 2012, Thompson-Webb held many leadership positions, with a clear focus on customer needs and aligning company objectives to meet those needs.

Thompson-Webb earned her Bachelor of Science in Biology from Indiana University, Bloomington, Indiana.

Howren brings over 25 years in the life sciences industry, including 10 years of business development leadership experience. Before joining Aldevron, Howren served as Vice President, Global Commercial Operations, Life Sciences Division at Meridian Bioscience. He also spent nearly 15 years at Thermo Fisher Scientific Corporation in a variety of business development positions of increasing responsibility, ending as the lead for global strategy focusing on human molecular diagnostics and mRNA therapeutics.

Howren earned his Bachelor of Science in Biology from Baylor University, Waco, Texas, and his Ph.D. in Physiology and Biophysics from the University of Arkansas for Medical Sciences, Little Rock, Arkansas. He has published several scientific papers and is an accomplished presenting expert at conferences and symposiums worldwide.

About Aldevron

Aldevron is a privately held company founded in 1998, and it has been setting the industry standard for quality, reliability and expertise since its inception. The Company continues to support thousands of clients around the globe who require plasmids, proteins, and mRNA for research, clinical, and commercial applications. Aldevron is known for inventing the GMP-Source® quality system, and for specializing in GMP manufacturing. In September of 2018, it opened the world’s largest pDNA facility on its 14-acre company headquarter campus in Fargo, North Dakota. Aldevron’s 189,000 square foot GMP capacity expansion and its dedicated 45,000 square foot research grade facility are both scheduled to begin product manufacture in Q2 of 2021. The Company’s protein development and manufacturing operations for R&D applications are located in Madison, Wisconsin. Aldevron employs nearly 600 people across its two locations. Visit www.aldevron.com for more information.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.